Why Pfizer's stumble in the obesity market is a boon for Eli Lilly - CNBC
- Why Pfizer's stumble in the obesity market is a boon for Eli Lilly CNBC
- Pfizer Stops Developing Weight-Loss Pill Bloomberg Television
- Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity Yahoo Finance
- Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects CNBC
- Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal STAT
- View Full Coverage on Google News